Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 1148-1154

  Cowen, Didier ^a,f   Troncoso, Patricia ^b   Khoo, Vincent S ^a,g   Zagars, Gunar K ^c   Von Eschenbach, Andrew C ^d   Meistrich, Marvin L ^a   Pollack, Alan ^e  

^a Departments of Experimental Radiation Oncology   (United States)

^b Departments of Pathology   (United States)

^c Radiation Oncology   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f INSTITUT PAOLI CALMETTES   (France)

^g CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER STAGING; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSURETHRAL RESECTION; TREATMENT FAILURE;

COHORT STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036096949     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Observations on the doubling time of prostate cancer: The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
2. Pretreatment prostate specific doubling times: Clinical utility of this predictor of prostate cancer behavior
3. Implication of cell kinetic changes during progression of human prostatic cancer
4. Immunocytochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma
5. Association between in vivo iododeoxyuridine labeling, MIB-1 expression, malignancy grade and clinical stage in human prostate cancer
6. Cell kinetic measurements in prostate cancer
7. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy
8. The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation
9. Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma
10. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction
11. Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models
12. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression
13. Direct comparison of bromodeoxyuridine and Ki-67 labeling indices in human turnouts
14. Ki-67 labeling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy
15. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy
16. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery
17. Proliferative index determination in prostate carcinoma tissue: Is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage?
18. Cell proliferation assessed by Ki-67 immunoreactivity of formalin fixed tissues is a predictive factor for survival in prostate cancer
19. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly
20. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferation rate are independent predictive markers for recurrence in prostate cancer
21. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas
22. The prognostic significance of proliferation-associated nuclear protein p120 expression in prostate adenocarcinoma: A comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen and p34cdc2
23. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy
24. Consensus statement: Guidelines for PSA following radiation therapy
25. External beam radiotherapy dose-response characteristics of 1127 men with prostate cancer treated in the PSA era
26. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and cell adhesion protein CD44s in surgically treated patients with prostate cancer
27. Quantitative analysis of the decay of immunoreactivity in stored prostate needle biopsy sections
28. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting
29. Abnormal expression of MDM2 in prostate carcinoma
30. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity
31. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy